Treatment of pediatric acute lymphoblastic leukemia: Progress achieved and challenges remaining

被引：4
作者：
Gaynon P.S. [1 ]
机构：
[1] Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027
来源：
Current Hematologic Malignancy Reports | 2007年 / 2卷 / 3期
关键词：
Acute Lymphoblastic Leukemia; Minimal Residual Disease; Acute Lymphoblastic Leukaemia; Asparaginase; Central Nervous System Relapse;
D O I：
10.1007/s11899-007-0026-y
中图分类号：
学科分类号：
摘要：
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Careful building upon past clinical trials and thoughtful application of our limited knowledge of pharmacology have provided steady improvement in outcome for newly diagnosed patients. Precise identification of the many patients who are unlikely to relapse with current effective regimens is required to avoid the morbidity of further intensification of therapy. Progress is sorely lacking for relapsed patients. Most patients who relapse die. Gene expression arrays and comparative genomic hybridization have further extended our appreciation of the known immunophenotypic and genetic diversity of childhood ALL. Insight into the molecular mechanisms of treatment failure may provide guidance for future efforts. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：193 / 201
页数：8
相关论文
共 78 条
  • [1] Gaynon P.S., Trigg M.E., Heerema N.A., Et al., Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995, Leukemia, 14, pp. 2223-2233, (2000)
  • [2] Pui C.H., Boyett J.M., Rivera G.K., Et al., Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital, Leukemia, 14, pp. 2286-2294, (2000)
  • [3] Schrappe M., Reiter A., Zimmermann M., Et al., Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster, Leukemia, 14, pp. 2205-2222, (2000)
  • [4] Silverman L.B., Declerck L., Gelber R.D., Et al., Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia, Leukemia, 14, pp. 2247-2256, (2000)
  • [5] Jemal A., Murray T., Ward E., Et al., Cancer statistics, 2005, CA Cancer J Clin, 55, pp. 10-30, (2005)
  • [6] Chessells J.M., Veys P., Kempski H., Et al., Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia, Br J Haematol, 123, pp. 396-405, (2003)
  • [7] Nguyen K., Cheng S.C., Raetz E., Et al., Factors influencing survival after relapse from childhood ALL: A Children's Oncology Group study [abstract], Blood (ASH Annual Meeting Abstracts), 108, (1855)
  • [8] Cave H., van der Werff ten Bosch J., Suciu S., Et al., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group, N Engl J Med, 339, pp. 591-598, (1998)
  • [9] van Dongen J.J., Seriu T., Panzer-Grumayer E.R., Et al., Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood, Lancet, 352, pp. 1731-1738, (1998)
  • [10] Donadieu J., Auclerc M.F., Baruchel A., Et al., Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: Differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French Acute Lymphoblastic Leukaemia study group, Br J Haematol, 102, pp. 729-739, (1998)
12345678